Dr. James Dugan
Claim this profileNovant Health
Area of expertise
Acute Myelogenous Leukemia
James Dugan has run 4 trials for Acute Myelogenous Leukemia. Some of their research focus areas include:
Acute Myeloid Leukemia
James Dugan has run 4 trials for Acute Myeloid Leukemia. Some of their research focus areas include:
Affiliated Hospitals
Novant Health
Novant Health Hematology - Forsyth
Clinical Trials James Dugan is currently running
DFP-10917
for Acute Myeloid Leukemia
Phase III, multicenter, randomized study with two arms (1:1 ratio) enrolling patients with AML relapsed/refractory after 2, 3, or 4 prior induction regimens: Experimental arm: DFP-10917 14-day continuous intravenous (IV) infusion at a dose of 6 mg/m²/day followed by a 14-day resting period per 28-day cycles. Control arm: Non-Intensive Reinduction (LoDAC, Azacitidine, Decitabine, Venetoclax Combination Regimens) or Intensive Reinduction (High and Intermediate Dose Cytarabine Regimens), depending on the patient's prior induction treatment.
Recruiting
2 awards
Phase 3
4 criteria
Emavusertib (+ Venetoclax)
for Acute Myeloid Leukemia
This is a multicenter, open-label, Phase 1/2a dose escalation and expansion study of orally administered emavusertib (CA-4948) monotherapy in adult patients with AML or higher- risk Myelodysplastic Syndrome (hrMDS). Patients enrolling in the Phase 1 dose escalation of the study must meet one of the following criteria prior to consenting to the study: * Relapse/refractory (R/R) AML with FMS-like tyrosine kinase-3 (FLT3) mutations who have been previously treated with a FLT3 inhibitor * R/R AML with spliceosome mutations of splicing factor 3B subunit 1 (SF3B1) or U2AF1 * R/R hrMDS with spliceosome mutations of SF3B1 or U2 small nuclear RNA auxiliary factor 1 (U2AF1) * Number of pretreatments: 1 or 2 The Phase 2a Dose Expansion will be in 3 Cohorts of patients: 1. R/R AML with FLT3 mutations who have been previously treated with a FLT3 inhibitor; 2. R/R AML with spliceosome mutations of SF3B1 or U2AF1; and 3. R/R hrMDS (Revised International Prognostic Scoring System \[IPSS-R\] score \> 3.5) with spliceosome mutations of SF3B1 or U2AF1. All patients above have had ≤ 2 lines of prior systemic anticancer treatment. In previous versions of this protocol there was a Phase 1b portion of the study, in which patients with AML or hrMDS received CA-4948 in combination with venetoclax. This part of the study is no longer open for enrollment.
Recruiting
1 award
Phase 1 & 2
9 criteria
More about James Dugan
Clinical Trial Related
4 years of experience running clinical trials · Led 6 trials as a Principal Investigator · 2 Active Clinical Trials
Treatments James Dugan has experience with
- Azacitidine
- Venetoclax
- Tamibarotene
- CA-4948
- Asciminib
- DFP-10917
Breakdown of trials James Dugan has run
Acute Myelogenous Leukemia
Acute Myeloid Leukemia
Myelodysplastic Syndrome
Hereditary Sensory Neuropathy
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does James Dugan specialize in?
James Dugan focuses on Acute Myelogenous Leukemia and Acute Myeloid Leukemia. In particular, much of their work with Acute Myelogenous Leukemia has involved SF3B1 positive patients, or patients who are U2AF1 positive.
Is James Dugan currently recruiting for clinical trials?
Yes, James Dugan is currently recruiting for 2 clinical trials in Winston-Salem North Carolina. If you're interested in participating, you should apply.
Are there any treatments that James Dugan has studied deeply?
Yes, James Dugan has studied treatments such as Azacitidine, Venetoclax, Tamibarotene.
What is the best way to schedule an appointment with James Dugan?
Apply for one of the trials that James Dugan is conducting.
What is the office address of James Dugan?
The office of James Dugan is located at: Novant Health, Winston-Salem, North Carolina 27103 United States. This is the address for their practice at the Novant Health.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.